RecruitingNCT05265429
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Studying NUT midline carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- Pasi A Janne, MD, PhD, MD PHDDana-Farber Cancer Institute
- Intervention
- Data and Specimen Collection(genetic)
- Enrollment
- 500 target
- Eligibility
- 15 years · All sexes
- Timeline
- 2023 – 2027
Study locations (4)
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05265429 on ClinicalTrials.govOther trials for NUT midline carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07050186Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT CarcinomaNorthwestern University
- RECRUITINGPHASE1NCT05372640Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT07459127Multicenter Retrospective Cohort of Pulmonary NUT CarcinomaThree Gorges Hospital of Chongqing University
- RECRUITINGPHASE1, PHASE2NCT05019716Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT CarcinomaNational Cancer Institute (NCI)